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Abstract A RRKRRQ sequence unique to the LG3 module of
the laminin K2 chain was previously shown to be sensitive to
endogenous proteolysis during the recombinant production of the
tandem array K2LG1-3. Mutation of RQ surrounding the
cleaved peptide bond did not prevent this processing and
intracellular degradation. Alanine mutagenesis of three alternate
basic residues, however, was shown to prevent the cleavage in
K2LG1-3, allowing for the K2LG3 module to be obtained as a
folded, globular fragment. The mutation did not change heparin
and sulfatide binding or cell adhesion of K2LG1-3 which can be
mediated by K3L1 and K6L1 integrins. It did, however, cause a
10-fold reduction in K-dystroglycan binding. The data favor the
interpretation that binding epitopes for heparin/sulfatides, L1
integrins and K-dystroglycan occupy different parts of the
K2LG1-3 structure.
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1. Introduction
Laminins are abundant basement membrane proteins which
assemble into heterotrimers (KLQ) and are involved in cellular
interactions and in the supramolecular organization of large
extracellular structures [1]. They exist as at least 11 di¡erent
isoforms based on ¢ve K chains, K1^K5, which have as a
characteristic feature a large globular G domain (about 1000
residues) at their C-terminal end. This G domain consists of a
tandem array of ¢ve LG modules with moderate sequence
identities (20^30%) and similar modules have been identi¢ed
in several other extracellular and transmembrane proteins
[1,2]. The major functions of the LG modules of laminins
are considered to be the promotion of cell adhesion through
integrins [3] and K-dystroglycan [4] and the binding of hepa-
rin, sulfatides and several extracellular matrix ligands [5^8].
This has led to several recombinant studies in mammalian and
insect cells in order to analyze structure-function relationships
[7^11]. The data demonstrated that LG modules represent
autonomous folding units [9,11]. Furthermore, similar binding
functions identi¢ed for laminin K1 and K2 chains are located
on di¡erent modules such as K1LG4 and K2LG5 [8].
In previous studies, we have prepared the individual lami-
nin K2 LG modules K2LG1, K2LG2, K2LG4 and K2LG5 as
well as the tandem arrays K2LG1-3 and K2LG4-5 by recombi-
nant production in mammalian cells [9]. Functional analyses
demonstrated that heparin and sulfatide binding are shared by
several but not all LG modules, while binding to K-dystrogly-
can required tandem arrays [8]. Previous data for K2 chain-
containing laminins derived from tissues have also indicated
that limited proteolysis takes place and in the recombinant
fragment K2LG1-3, the cleavage site could be located to a
unique sequence of ¢ve basic residues joined to a glutamine
in the K2LG3 module [9]. The two fragments of K2LG1-3
remained non-covalently associated. The same cleavage may
have occurred in the recombinant production of K2LG3
where it apparently initiated a complete intracellular destruc-
tion of the module.
In the present study, we have used site-directed mutagenesis
of the protease cleavage region of K2LG3 in order to study
requirements for endogenous proteolysis as well as the e¡ects
on binding activities. This demonstrated that proteolysis could
be abolished by changing the basic nature of this sequence but
not by changing the two residues which contribute to the
natural cleavage site. Lack of cleavage had no e¡ect on L1
integrin-mediated cell adhesion to K2LG1-3 but distinctly re-
duced K-dystroglycan binding.
2. Materials and methods
2.1. Vector construction and recombinant protein production
The mouse laminin K2 chain LG1-3 domain construct [9] was used
as a template for the construction of vectors encoding mutants of the
protease-sensitive site in K2LG3. Two di¡erent mutations, 1 (intro-
ducing the amino acid changes R2571A, K2573A and R2575A) and 2
(introducing the amino acid changes R2575A and Q2576A), were
produced. Site-directed mutagenesis was accomplished by overlap ex-
tension PCR with Vent Polymerase. In order to introduce mutation 1,
the 5P mutational primer ACACCACCCGCGAGAGCACGGGCA-
CAAACCACA was used with the K2LG3 3P primer and the 3P muta-
tional primer TGTGGTTTGTGCCCGTGCTCTCGCGGGTGGT-
GT was used together with the 5P primer for K2LG3 or K2LG1 [9]
to produce K2LG3 mutant 1 or K2LG1-3 mutant 1, respectively. The
overlapping PCR products were annealed and PCR was used to ex-
tend them to their full length. For mutant 2, the same strategy was
used. Mutations were introduced into the template using the primers
AGAAAACGGGCAGCAACCACACAG and CTGTGTGGTTG-
CTGCCCGTTTTCT in addition to the terminal primers for
K2LG3. PCR products were veri¢ed by sequencing and ligated into
plasmid pCEP/pu [14] as described [9]. Human embryonic kidney cells
293 which constitutively express the EBNA-1 protein from Epstein-
Barr virus (293-EBNA, Invitrogen) were transfected with the con-
structs. Transfectants were selected with 0.5 Wg/ml puromycin (Sigma)
and 250 Wg/ml G418 (Gibco), washed extensively in phosphate-
bu¡ered saline and grown in serum-free DMEM/F12 medium (Gibco)
for 2 days after which medium was harvested and new serum-free
medium added for another 2 days.
2.2. Puri¢cation and sources of proteins
Conditioned serum-free medium of K2LG mutants was dialyzed
against 50 mM Tris-HCl, pH 7.4, containing phenylmethylsulfonyl
£uoride (Serva) and N-ethylmaleimide (Merck). Recombinant pro-
teins were isolated on a heparin a⁄nity column (2U30 cm) equili-
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brated in the same bu¡er. Proteins were eluted with a linear NaCl
gradient (0^0.6 M, 500 ml). After puri¢cation on a Superose-12 col-
umn (HR 16/50, Pharmacia) equilibrated in 0.2 M ammonium acetate,
pH 6.8, they were lyophilized and dissolved in 0.2 M NH4HCO3.
Other K2LG fragments were those previously described [9]. Chicken
kidney K-dystroglycan was kindly supplied by A. Brancaccio [15,16].
Heparin coupled to bovine serum albumin and bovine brain sulfatides
were from a commercial source (Sigma).
2.3. Analytical and binding assays
Protein samples were hydrolyzed with 6 M HCl (16 h, 110‡C) in
order to determine their concentrations on a Biotronik LC3000 amino
acid analyzer. N-terminal sequencing and rotary shadowing electron
microscopy followed established protocols. Solid phase binding assays
with immobilized heparin-albumin, sulfatides and K-dystroglycan and
analytical heparin a⁄nity chromatography were according to previ-
ously used methods [8]. Cell adhesion assays based on crystal violet
staining and colorimetry [17] were carried out with cell lines previ-
ously shown to adhere to K2 chain-containing laminins [13] but also
included C2C12 muscle cells provided by U. Mayer. Inhibitors were
added to the cells prior to seeding them onto the substrates. Inhibitory
monoclonal antibodies to human integrin subunits were those used
previously [13].
3. Results
The K2LG3 module of the mouse and human laminin K2
chain [18,19] contains a unique basic sequence RRKRRQ
(position 2571^2576) which was shown to be completely
cleaved at the RQ site by an unknown protease in the re-
combinant production of the tandem array K2LG1-3 in mam-
malian cells [9]. This cleavage was apparently also responsible
for the failure to obtain K2LG3 in a recombinant form. This
cleavage region was now studied by site-directed mutagenesis
(Fig. 1A) in order to replace three basic residues by alanines
(mutant 1) or to change the cleavage site to an Ala-Ala se-
quence (mutant 2). The mutations were introduced into ex-
pression vectors for K2LG1-3 and/or K2LG3 and all gave rise
to high levels of speci¢c mRNA in transfected human EBNA-
293 cells (Fig. 1B). Analysis of serum-free culture medium by
SDS-gel electrophoresis was used to identify production of the
recombinant proteins as indicated in Fig. 1A. This is illus-
trated for K2LG3 and its mutants and showed only for mu-
tant 1 the expected band of 34 kDa (Fig. 1C, lane 3) when
compared to medium of non-transfected cells (Fig. 1C, lane
1). Medium of K2LG3 mutant 2 showed instead two weaker
extra bands of 30 and 26 kDa (Fig. 1C, lane 4). These two
weak bands both started with an AATTQAYY sequence,
demonstrating cleavage of the novel Arg-Ala bond in mutant
2. This is then very likely followed by extensive degradation of
the recombinant product.
Mutant 1 variants of K2LG1-3 and K2LG3 could be e⁄-
ciently puri¢ed by heparin and molecular sieve chromatogra-
phy, as shown by electrophoresis (Fig. 1D). They started with
a single APLAGGD (K2LG1-3, position 2147) or APLAVE-
LA (K2LG3, position 2533) sequence, with APLA being de-
rived from the signal peptide cleavage region of the expression
vectors [14]. Rotary shadowing electron microscopy of both
mutants demonstrated a rather uniform population of globu-
lar particles which, as expected, di¡ered in size (Fig. 2). This
strongly indicated that the mutation has not interfered with
proper folding of the proteins.
The K2LG1-3 and K2LG3 mutants 1 were also compared
with the processed K2LG1-3 (see Fig. 1D) in various binding
assays (Table 1). In analytical heparin a⁄nity chromatogra-
phy, the mutants eluted from the column at a lower ionic
strength (0.2 M NaCl) than K2LG1-3 (0.36 M NaCl). In solid
Fig. 1. Mutations in the protease-sensitive region of the laminin
K2LG3 module and their e¡ects on recombinant production. A:
The mutations were introduced in a basic hexapeptide region (posi-
tion 2571^2576 of the mouse laminin K2 chain) and are shown in
bold. An arrowhead marks the cleavage site in the wild-type se-
quence. Both mutations were introduced in episomal expression vec-
tors encoding the tandem array K2LG1-3 and mutation 1 also in
the K2LG3 module alone. Their e¡ects on protein production and
protease cleavage are schematically outlined. Probable intracellular
degradation is denoted by (id). One of the potential vectors was not
done (nd). The data for the wild-type are from [9]. B: Northern
blots show the e⁄ciency of 293-EBNA cell transfections with vec-
tors for K2LG1-3 mutant 1 (lane 1), K2LG3 mutant 1 (lane 2) and
K2LG3 mutant 2 (lane 3). C: SDS-gel electrophoresis of serum-free
medium from non-transfected EBNA-293 cells (lane 1) and cells
transfected with K2LG3 (lane 2) or its mutants 1 (lane 3) and 2
(lane 4). Only lane 3 showed a characteristic 34 kDa band. Two
weak bands in lane 4 (marked by arrowheads) were shown to be
fragments of K2LG3. D: SDS-gel electrophoresis of puri¢ed re-
combinant wild-type K2LG1-3 (lane 1), K2LG1-3 mutant 1 (lane 2)
and K2LG3 mutant 1 (lane 3).
Table 1
E¡ect of mutations in the protease-sensitive region of K2LG3 on binding to immobilized ligands
Soluble ligands Heparin Sulfatides (nM)c K-Dystroglycan (nM)c
(M NaCl)a (nM)b
K2LG1-3 0.36 50 60 25
K2LG1-3 mutant 1 0.20 110 110 150
K2LG3 mutant 1 0.19 80 80 300
aHeparin a⁄nity chromatography in 0.05 M Tris-HCl, pH 7.4, showing the NaCl concentration required for displacement.
bSolid phase assays with immobilized heparin-albumin conjugate recording the concentrations required for half-maximal binding.
cHalf-maximal binding to immobilized sulfatides and K-dystroglycan.
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phase binding assays carried out at physiological ionic
strength, however, only marginal di¡erences were observed
in the binding of the three components to immobilized hep-
arin-albumin conjugate and to sulfatides. A clear 6^12-fold
reduction in binding a⁄nity for K-dystroglycan was observed
for both mutants.
Human placental laminin-2 and -4, which contain the K2
chain, were previously shown to promote strong adhesion of
HBL-100, HT1080 and Rugli cells mediated through L1 in-
tegrins [13]. These and some other cell lines were now used to
analyze the adhesive properties of various recombinant LG
modules of the mouse laminin K2 chain. As shown for human
HBL-100 cells, fragments K2LG1-3 and K2LG1-3 mutant 1
showed nearly identical dose-response pro¢les to laminin-2/-4
(Fig. 3) and adhesion was followed by distinct cell spreading.
No or only low adhesion was observed to all other fragments,
including K2LG4-5 and individual LG modules. Similar activ-
ities were found for rat RN22 and Rugli tumor cells and for
the muscle cell line C2C12. Fragment K2LG1-3 was, however,
only a poor substrate for human HT1080 cells. HBL-100 cell
adhesion to K2LG1-3 was also examined in the presence of
blocking monoclonal antibodies against human integrin sub-
units (Fig. 4). Nearly complete inhibition was observed with
anti-L1 antibodies but only partial inhibition with antibodies
against K3 and K6 subunits. Furthermore, a synthetic
GRGDS peptide was non-inhibitory up to 0.4 mM for the
adhesion of Rugli, RN22 and C2C12 cells to K2LG1-3. No
inhibition was observed for heparin (1 mg/ml) in assays with
HBL-100, RN22 and Rugli cells.
4. Discussion
Among the 11 laminin isoforms identi¢ed so far, only a few
of them are known to undergo limited proteolysis during or
after assembly and secretion. Laminin-5 (chain composition
K3L3Q2) is cleaved at several sites to allow for integration into
anchoring ¢laments [20] and cleavage apparently occurs at a
single site in the K2 chain of laminin-2 and -4 [12,13]. The
latter was localized to an Arg-Gln bond pre¢xed by a stretch
of basic residues and caused the cyclization of the liberated
Gln. This indicated that this processing involved either furin-
type proteases requiring basic motifs or a procollagen pepti-
dase acting on Gln [9]. The mutational data shown here dem-
onstrated that an uninterrupted basic sequence determines
cleavage and not the presence of a C-terminal Gln which
can be replaced by Ala. The minimum basic sequence for
furin cleavage is BXBB [21] and further studies will be needed
to show whether this is su⁄cient for K2LG3 conversion. The
Fig. 2. Electron micrographs of rotary-shadowed K2LG1-3 mutant 1
(A) and K2LG3 mutant 1 (B). Note the rather uniform globular
structures which di¡er in size. Bar: 100 nm.
Fig. 3. Adhesion pro¢les of human HBL-100 cells to K2 chain-con-
taining laminins and recombinant fragments of the G domain. Sub-
strates used were a mixture of laminin-2 and -4 (b) and fragments
K2LG1-3 (a), K2LG1-3 mutant 1 (R), K2LG4-5 (O), K2LG1 (S),
K2LG2 (O) and K2LG3 mutant 1 (E).
Fig. 4. Inhibition of adhesion of HBL-100 cells to integrin subunits
L1 (a), K3 (O) and K6 (E) by monoclonal antibodies. They were
used as hybridoma media at the dilutions indicated.
FEBS 22622 16-9-99
J.F. Talts, R. Timpl/FEBS Letters 458 (1999) 319^323 321
crystal structure of the K2LG5 module has recently been de-
termined and showed a compact L sandwich [22]. Homology
modeling of K2LG3 onto this structure located the basic se-
quence to an extended loop between L strands D and E and is
therefore well-exposed for cleavage. Mutation 1 also facili-
tated production of recombinant fragments K2LG1-3 and
K2LG3 in a non-processed form and these were used to study
the role of proteolytic cleavage and/or the basic sequence in
various binding assays.
Mutation 1 had no e¡ect on heparin/sulfatide binding in
solid phase assays but lowered the salt concentration required
to elute K2LG1-3 from heparin. Fragment K2LG1-3 has an-
other heparin binding site on the K2LG1 module (which elutes
at 0.14 M NaCl) [8] and it could well be that the mutation
interfered with a cooperativity between LG1 and LG3 binding
sites when present in a tandem array. The major binding site
of the laminin K1 chain for heparin and sulfatides has been
localized to the K1LG4 module and, as shown by mutations,
both binding epitopes are nearly identical. The cellular recep-
tor K-dystroglycan also binds to this epitope plus some other
residues [11] and this is in agreement with the e⁄cient inhib-
ition of K-dystroglycan binding to K1LG4-5 by heparin. The
latter inhibition was not observed for K-dystroglycan binding
to recombinant K2LG1-3 and K2LG4-5, indicating that the
binding epitopes on the K2 chain are substantially di¡erent
from those on the K1 chain [8]. This interpretation is now
further supported by a 10-fold decrease in binding a⁄nity
of K-dystroglycan by introducing the mutation 1 into
K2LG3. This a⁄nity is as low as that described for K1LG4
[8,11] and may be caused by a lack of proteolytic activation or
directly by interference with the binding epitope through in-
dividual mutations.
Salt-extracted laminin-2 and -4 were previously shown to
mediate strong cell adhesion via L1 integrins [13]. Our data
indicate that adhesion of at least some cells is due to the
K2LG1-3 structure. In the case of HBL-100 cells, the interac-
tion is mediated through K3L1 and K6L1 integrins, as indi-
cated by antibody inhibition. These two integrins are well-
established laminin receptors [3] and have also been impli-
cated in cell binding to placental laminin preparations ob-
tained by limited pepsin digestion [23,24], which very likely
contain substantial amounts of K2 chain laminins. Yet, adhe-
sion of HT1080 cells to laminin-2 and -4 could not be inhib-
ited by antibodies to K3 and K6 integrins [13], in agreement
with their low adhesion to K2LG1-3. These cells were recently
shown to bind to an N-terminal structure of the K2 chain
through K1L1 and K2L1 integrins [25]. Another function as-
cribed to the C-terminal G domain of the laminin K2 chain is
the neural targeting of Mycobacterium leprae, where it medi-
ates through its LG modules binding to L4 integrins [10]. This
implicates a second binding site within the K2LG1-5 structure
for bacterial receptors. The L1 integrin binding site on
K2LG1-3 could not be mapped to individual LG modules,
but should not include heparin binding epitopes, as shown
in inhibition assays.
We have also provided some initial evidence that the bind-
ing epitopes for L1 integrins and K-dystroglycan should be
di¡erent, since mutation 1 modulates the latter activity but
not cell adhesion. Both cellular receptors are important for
early embryonic development, as shown in transgenic mice
which lack the L1 integrin [26,27] or K-dystroglycan [28]. Fur-
thermore, a lack of laminin K2 chain causes severe forms of
muscular dystrophy [29,30]. A possible molecular explanation
for the receptor de¢ciencies was also analyzed in homozygous
(3/3) embryonic stem cells which demonstrated a crucial role
for L1 integrins [31] and K-dystroglycan [32] in the correct
formation of basement membranes either in teratomas or em-
bryoid bodies. Based on these observations, we speculate on a
distinct interplay of laminin K2LG modules with both recep-
tor-types [33] with these interactions possibly also being
modulated by limited proteolysis. Further mutational analysis
and a precise measurement of binding a⁄nities will be needed
to further substantiate such possibilities.
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